Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
breast cancer
Biotech
Pfizer's $1B protein degradation bet yields 3% response rate
After a publication snafu, Arvinas posted the breast cancer results ahead of schedule—and revealed one response among 35 patients at its phase 3 dose.
Nick Paul Taylor
Nov 22, 2022 9:40am
Pfizer discards eczema, NASH and breast cancer programs
Nov 1, 2022 9:50am
AstraZeneca scores breast cancer wins for AKT and SERD drugs
Oct 26, 2022 5:50am
Roche nets FDA approval for HER2-low breast cancer test
Oct 5, 2022 11:30am
Puma pounces on failed Takeda drug, snapping up cancer prospect
Sep 21, 2022 9:05am
FAK inhibitors block breast cancer brain metastasis in mice
Sep 12, 2022 1:57pm
